Cited 1 times since 2015 (0.1 per year) source: EuropePMC Personalized medicine, Volume 12, Issue 2, 1 1 2015, Pages 63-66 Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. Kuiper JL, Bahce I, Voorhoeve C, Yaqub M, Heideman DA, Thunnissen E, Paul MA, Postmus PE, Hendrikse NH, Smit EF
Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future.
